MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2020
Continued focus on MIV-818July – SeptemberSignificant events during the quarter · In July, a research collaboration was initiated with the Drug Discovery and Development Platform (DDD) at SciLifeLab on potential inhibitors of SARS CoV-2. Through the collaboration, DDD will get access to Medivir’s unique proprietary protease-targeted compound library. Financial summary for the quarter · Net turnover amounted to SEK 1.1 (1.7) million. · The profit before interest, tax, depreciation and amortization (EBITDA) amounted to SEK 5.2 (-22.0) million. Basic and diluted earnings per